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Abstract
Background: With the renewed emphasis to implement isoniazid preventive therapy (IPT) in Sub-Saharan Africa,
we investigated the effect of IPT on immunological profiles among household contacts with latent tuberculosis.
Methods: Household contacts of confirmed tuberculosis patients were tested for latent tuberculosis using the
QuantiFERON®-TB Gold In-Tube (QFN) assay and tuberculin skin test (TST). HIV negative contacts aged above
5 years, positive to both QFN and TST, were randomly assigned to IPT and monthly visits or monthly visits only.
QFN culture supernatants from enrolment and six months’ follow-up were analysed for M.tb-specific Th1, Th2, Th17,
and regulatory cytokines by Luminex assay, and for M.tb-specific IgG antibody concentrations by ELISA. Effects of
IPT were assessed as the net cytokine and antibody production at the end of six months.
Results: Sixteen percent of contacts investigated (47/291) were randomised to IPT (n = 24) or no IPT (n = 23). After
adjusting for baseline cytokine or antibody responses, and for presence of a BCG scar, IPT (compared to no IPT)
resulted in a relative decline in M.tb-specific production of IFN gamma (adjusted mean difference at the end of six
months (bootstrap 95 % confidence interval (CI), p-value) -1488.6 pg/ml ((−2682.5, −294.8), p = 0.01), and IL- 2
(−213.1 pg/ml (−419.2, −7.0), p = 0.04). A similar decline was found in anti-CFP-10 antibody levels (adjusted geometric
mean ratio (bootstrap 95 % CI), p-value) 0.58 ((0.35, 0.98), p = 0.04). We found no effect on M.tb-specific Th2 or
regulatory or Th17 cytokine responses, or on antibody concentrations to PPD and ESAT-6.
Conclusions: IPT led to a decrease in Th1 cytokine production, and also in the anti CFP-10 antibody concentration.
This could be secondary to a reduction in mycobacterial burden or as a possible direct effect of isoniazid induced
T cell apoptosis, and may have implications for protective immunity following IPT in tuberculosis-endemic countries.
Trial registration: ISRCTN registry, ISRCTN15705625. Registered on 30th September 2015.
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Background
Adaptive immune responses to Mycobacterium tubercu-
losis (M.tb) infection and disease vary widely and are
heterogeneous between infected individuals [1]. During
the early stages of infection with tuberculosis there is a
high T helper (Th) 1, and to some extent Th17, immune
response to M.tb antigens [2, 3]. As mycobacteria multi-
ply and M.tb infection progresses to disease, Th1 and
Th17 responses tend to be suppressed and Th2 and
regulatory responses emerge. Of note, interleukin (IL)-4,
is associated with marked immunopathology and in-
creased severity of the disease [4]. Certain M.tb strains,
such as some subtypes of the W-Beijing strain, are asso-
ciated with prominent Th2 type responses and inhibition
of Th1 immune responses, and these strains are charac-
terised by greater severity of tuberculosis infection and
disease [5, 6]. The effects of IL-4 are accentuated in the
presence of the Th1 cytokine tumour necrosis factor
alpha (TNFα) [7, 8].
Persons with active tuberculosis also tend to have
increased production of IL-10 compared to those with la-
tent infection [9]. M.tb uses the lipoarabinomannan
(LAM) molecule in the cell wall to induce immune regula-
tion pathways through transforming growth factor beta
(TGFβ) and regulatory T cells that suppress protective
immune responses [10–12]. This same molecule, when
mannosylated, interacts with mannose receptors to drive
dendritic cells to release the regulatory cytokine IL-10
[13]. The IL-10 inhibits antigen processing and presenta-
tion during tuberculosis infection [14] and suppresses
Th1, Th2 and Th17 function [15–18]. Thus, there is a
delicate balance between pro-inflammatory immune re-
sponses that recognise M.tb infection, and conceal it by
promoting granuloma formation, and regulatory immune
responses that, while supressing Th1, Th2 and Th17 func-
tion to prevent immunopathology, may support mycobac-
terial replication and disease progression [18–22].
Extensive work has been carried out on treating per-
sons with latent tuberculosis using Isoniazid Preventive
Therapy (IPT). Early studies suggested a lifetime protec-
tion against active tuberculosis [23–25], but later studies
have shown waning protection following short term iso-
niazid based regimens [26, 27]. Despite this, benefits of
IPT have been demonstrated in high risk groups such as
those living with HIV infection and who are latently in-
fected with tuberculosis, where IPT reduces the risk of
re-activation and progression to active tuberculosis by
over 70 %, and that of mortality by 25 % [28]. Currently,
the World Health Organisation (WHO) recommends
the use of IPT in HIV positive individuals and children
under the age of 5 years who are exposed to active tu-
berculosis [29].
We derived a hypothesis that household contacts of ac-
tive tuberculosis patients with latent tuberculosis infection
would present with mixed Th1/Th2 cytokine profiles,
dominated by high concentrations of Th1 cytokines (due
to recent exposure), but accompanied by Th2 and regula-
tory cytokine production as a result of the on-going im-
mune modulating effects of M.tb infection. Regulatory
profiles might be further enhanced in populations highly
exposed to environmental mycobacteria, as is the case in
Uganda [30].
We further hypothesised that treatment of these la-
tently infected people with isoniazid would halt or re-
verse the induction of the Th2 and regulatory immune
responses, causing a shift towards Th1 type immune re-
sponses. Previous studies in active tuberculosis have
shown that treatment reverses the immune equilibrium
from Th2 responses back to Th1 immune dominance
[25, 31]. A similar effect might contribute to the long
term protective effects of IPT.
We therefore initiated an exploratory trial nested in a
parent cohort to investigate the effect of IPT among
household contacts of active tuberculosis patients found
to have latent tuberculosis infection, by comparing the
immune responses among those who received six
months of IPT with those who did not receive IPT.
Methods
Study design
This was a nested study with a randomised design
within a cohort of household contacts exposed to patients
with sputum positive tuberculosis in Kampala city,
Uganda [32]. Participants were recruited from May 2011
to January 2012.
Eligibility criteria for participants
Household contacts of all age groups who were exposed
to sputum positive tuberculosis patients were enrolled
into the larger cohort study [32]. Household contacts
received HIV counselling and testing, and provided a
sample of 3mls of blood for the QuantiFERON®-TB Gold
In-Tube® test (Cellestis GmbH (Europe), Hannover,
Germany; QFN). After blood samples were drawn from
the household contacts, a tuberculin skin test (TST) was
placed using the Mantoux method, using 2 Tuberculin
Units (0.1 ml) of RT-23 purified protein derivative (PPD)
(Statens Serum Institute, Copenhagen, Denmark), and
read after 48–72 h. A positive response was a diameter
of the induration area of >5 mm for HIV positive house-
hold contacts and >10 mm for those who were HIV
negative [33].
The household contacts that were above the age of
5 years, were HIV negative, and tested positive on both
tests, were enrolled into the nested study and followed
for six months. Household contacts were excluded if
they had signs and symptoms of active TB disease, liver
disease or epilepsy.
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Intervention and investigations
Eligible household contacts were allocated sequential num-
bers at enrolment and a computer- generated list was used
to randomly assign them to receive either IPT and monthly
visits or monthly visits only. Household contacts in the IPT
arm were offered isoniazid (5 mg/kg to a max of 300 mg)
plus pyridoxine 25 mg daily for six months, which was self-
administered. Neither the participants nor the care pro-
viders were blinded to which household contact received or
did not receive IPT. Treatment of HIV negative, latently in-
fected (TST/QFT positive), household contacts above the
age of 5 years is neither Ugandan nor WHO policy, justify-
ing not treating the control group. Household contacts
who were HIV positive or under 5 years of age were offered
routine IPT (5 mg/kg to a max of 300 mg) plus pyridoxine
25 mg daily for six months, which was self-administered, ir-
respective of their latent tuberculosis status, according to
the World Health Organisation guidelines [34, 35].
Baseline questionnaires were administered to the house-
hold contacts and data on socio-demographics, household
characteristics, TB related risk factors and exposures, med-
ical history, and clinical findings were collected. Monthly
data on clinical symptoms suggestive of active tuberculosis
and possible side effects of isoniazid were collected. At the
end of the six month follow up period, both the QFN and
TST were repeated.
QFN supernatants from the household contacts were
analysed for cytokine responses using an 11-analyte Bio-
Plex Pro™ human cytokine bead array (Bio-Rad, Richmond,
USA) consisting of interferon gamma (IFNγ), IL-2, TNFα,
IL-4, IL-5, IL-13, IL-10, IL-17a, IL-17f, IL-21, and IL-22.
The QFN assays is a 24 h whole blood stimulation assay
using M.tb specific proteins (early secreted antigenic target
6 (ESAT-6), culture filtrate protein 10 (CFP-10), TB7.7)
which have better specificity than using BCG or PPD stim-
ulated whole blood assays. These cytokines were measured
from the nil (no antigen) and TB antigen (ESAT-6, CFP-10
and TB7.7 (p4)) tubes for each household contact. All the
cytokine results were within the linear range of the assay.
Detection limits were as follows: IFNγ (92.6-52,719 pg/ml),
IL-2 (2.1-17,772 pg/ml), TNFα(5.8-95,484 pg/ml)), Th2
cytokines (IL-4 (2.2-3,467 pg/ml), IL-5 (3.1-7,380 pg/ml),
IL-13 (3.7-3,137 pg/ml)), regulatory cytokine (IL-10
(2.2-8,840 pg/ml)), and Th17 cytokines (IL-17a (4.9-
12,235 pg/ml), IL-17f (3.04-18,668 pg/ml), IL-21 (8.97-
147,023 pg/ml), IL-22 (3.88-11,917 pg/ml). Data were
acquired using the Bio-Rad Luminex reader using Bio-
Plex manager 4.1 software.
M.tb-specific antibody concentrations were analysed
using an in-house IgG ELISA assay on baseline and end of
follow up QFN culture supernatant samples from the nil
(no antigen), antigen and mitogen tubes. The experiments
used Immulon® 4 HBX microtitre plates (Thermo
Scientific, USA) which were coated with 10 μg of PPD,
CFP-10, ESAT-6 antigens per well and incubated
overnight at 4 °C. The CFP-10 and ESAT-6 antigens were
provided by BEI Resources which is an initiative of the
National Institute of Allergy and Infectious Diseases and
PPD from Statens Serum Institute, Copenhagen,
Denmark. Plates were washed four times with Phosphate-
Buffered Saline (PBS; pH 7.4) containing 0.05 % Tween 20
(PBS-T). Each plate was then coated with eight two-fold
serial dilutions of human IgG reference standard at a top
concentration of 0.625 μg/ml. Plates were blocked with
1 % skimmed milk in PBS-T for 2 h at room temperature.
A dilution of 1 in 100 was made of each sample in PBS-T
with 0.1 % skimmed milk (assay buffer) after which 50 μl
was added to antigen-coated wells. After an incubation of
2 h at room temperature, the wells were washed as before
and incubated with 50 μl/well polyclonal rabbit anti-
human IgG conjugated with horseradish peroxidase
(Dako, Denmark) at 0.5 μg/ml for another hour at the
room temperature. Plates were then washed and
enzyme activity detected by incubation with 100 μl/well
o-phenylenediamine (Sigma-Aldrich, USA) containing
hydrogen peroxide for 15 min. The reaction was
stopped by addition of 25 μl/well 2 M sulphuric acid
and thereafter the optical density (OD) measured at test
wavelength 490 nm and reference wavelength 630 nm
using an ELISA plate reader (BioTek Instruments,
USA).
A pooled sample of unstimulated QFN culture super-
natants from 40 active TB cases was included on each
plate as a positive control for the assay. All samples and
positive controls were assayed in duplicate to minimise
effects of random variations in volumes due to pipetting
errors. The ODs from the human IgG standard concen-
trations on every plate were used to generate standard
reference curves for use in conversion of sample ODs to
antibody concentrations in μg/ml. The concentrations of
the control wells were subtracted from the test antigen
wells. The net concentration was converted to ng/ml for
analysis and presentation of the results.
Outcomes
The primary outcome measures were (1) net cytokine
responses and (2) Mtb specific antibody concentrations
at the end of six-months follow up. The secondary out-
comes assessed were spontaneous cytokine responses at
the end of six-months follow up, possible side effects
due to the IPT, and the effect of IPT on latent tubercu-
losis infection evidenced by changes in TST and QFN
test reactions at the end of six-months follow up.
We defined spontaneous cytokine production as the
cytokine concentration measured in the nil (no antigen)
tube and net cytokine production as the concentration
obtained after subtracting the spontaneous cytokine
Biraro et al. BMC Infectious Diseases  (2015) 15:438 Page 3 of 12
production from the amount produced in the TB anti-
gen stimulated tube (antigen tube).
Statistical methods
This was an exploratory study and the numbers enrolled
were based on availability and not on a planned sample
size. Data was analysed using STATA package version
12. Characteristics of participants in the two arms were
compared using simple frequency tables. Cytokine re-
sponses and antibody concentrations showed skewed
distributions and were described using medians and
interquartile ranges. Line graphs were plotted to show
the change in cytokine response and antibody concen-
tration between baseline and end of follow up.
Each outcome measure was compared between treat-
ment arms by fitting a multiple regression model with
terms for treatment arm, baseline level of the cytokine
or anti-body to control for individual variability, and
presence of a BCG scar which varied between the two
treatment arms and was associated with cytokine re-
sponses in this cohort [32]. The residuals from the fitted
models were examined for evidence of non-constant
variance, and a normal probability plot was used to
determine whether the assumption of normality was
reasonable. For cytokine responses, IFNγ and IL-2 met
the above criteria. For other cytokines there was little
evidence of non-constant variance, but several showed a
departure from normality. Therefore, for each cytokine,
the models were refitted with bootstrapping used to
estimate the standard errors. The bootstrapping instruc-
tions were set at a random-number seed of 468 with
1000 replications.
For the antibody concentrations, there was evidence of
non-constant variance, therefore a log transformation to
base 10 was carried out and the results interpreted on a
multiplicative scale. Because, in addition, there was still
evidence of non-normality after the log transformation,
bootstrapping was used to estimate the standard errors
in the transformed model. Each cytokine and antibody
was analysed separately.
Ethics approval
Both the Makerere University College of Health Sciences
Ethical Review Board and Uganda National Council for
Science and Technology approved the study. All adult
household contacts gave written informed consent to
participate in the study. Parents, next of kin, caretakers
or guardians gave written informed consent on behalf of
the minors or children to participate in the study. In
addition, children between 10 and 17 years also gave
written informed assent to participate in the study.
Results
Study participants
Of the 291 household contacts recruited at baseline, 47
(16 %) household contacts were eligible for randomisa-
tion and had positive results for both QFN assay and
TST. Two hundred and forty four household contacts
were excluded as follows: 93 (38 %) were eligible for rou-
tine IPT (children under 5 years and persons with HIV
infection), 52 (21 %) were negative for latent tuberculosis
infection (negative QFN and TST results), and 99 (41 %)
were positive on either QFN or TST but not both.
Figure 1 details the rest of the recruitment, randomisa-
tion, and follow up process. The baseline demographic
and exposure characteristics were similar in both arms
except for differences in the frequency of presence of a
BCG scar, and in the baseline cytokine concentrations.
The Th1 type cytokines had the highest concentrations
at baseline compared to Th2, regulatory, and Th17 cyto-
kines (Table 1).
Over 70 % of the household contacts in each arm
completed the study. The main reason for loss to follow
up was a change in the address of the household con-
tacts. The household contacts that withdrew from the
study were unable to continue with the follow up be-
cause of their busy schedules. All received six months
of IPT. There were no documented side effects of iso-
niazid treatment and there was no incidence of active
tuberculosis.
Effect of IPT on cytokine responses
This study was exploratory, comparing the effect of IPT
on net cytokine responses and antibody concentrations
at the end of follow up as the primary outcomes of inter-
est, among latently infected contacts who were above
5 years of age and were HIV negative. We observed a
drop in the M.tb-specific IFNγ and IL-2 cytokine produc-
tion in the IPT arm (median (IQR)) from 648.3 pg/ml
(259.5–2605.4) to 412.3 pg/ml (129.0–878.1), and from
291.1 pg/ml (80.6–444.3) to 179.8 pg/ml (62.5–322.4)
respectively, but no change or a slight rise in the no IPT
arm (Fig. 2).
The multiple linear regression models confirmed that
IPT caused a relative decline in the same Th1 cytokine
responses (Table 2). After adjusting for baseline cyto-
kine responses and presence of a BCG scar, there was a
lower net production of IFNγ in the IPT arm (adjusted
mean difference at the end of six months (bootstrap
95 % confidence interval, p-value) -1488.6 pg/ml
((−2682.5, −294.8), p = 0.01), and of IL- 2 (−213.1 pg/ml
(−419.2, −7.0); p = 0.04). However, IPT had no effect on
the Th2, regulatory and Th17 cytokine profiles (Table 2).
IPT had no effect on spontaneous cytokine production
at the end of six months.
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Effect of IPT on M.tb specific antibody concentrations
We assessed the effect of IPT on IgG antibody responses
to PPD, CFP-10, and ESAT-6 and found that there was
no major change in the absolute antibody concentrations
in either arm (Fig. 3). However, after adjusting for base-
line antibody concentration and presence of a BCG scar,
we observed that IPT caused a relative decline in the
antibody concentrations to CFP-10 (adjusted geometric
mean ratio (bootstrap 95 % CI), p-value) 0.58 (0.35,
0.98), p = 0.04. There was no effect on antibodies to
ESAT-6 or PPD (Table 3).
Effect of IPT on tuberculosis infection
We assessed the effect of IPT on M.tb infection by in-
vestigating the number of TST and QFN reversions
found at the end of six months of follow up. There was
only one QFN test reversion and it occurred in the IPT
arm. There were 26 TST reversions: 15/18 (83 %) of par-
ticipants assessed in the IPT arm showed TST reversions
and 11/17 (65 %) in the no-IPT arm (p = 0.26, Fisher’s
exact test). Among reverters, the average TST diameter
fell from 14 mm to 2 mm in the IPT arms and from
18 mm to 4 mm in the no IPT arm.
Discussion
In this study, we found that the household contacts of
active tuberculosis patients who had evidence of latent
M.tb infection had strong M.tb-specific Th1 cytokine
responses at baseline. Contrary to our hypothesis, we
found low production of Th2 cytokines which supports
evidence that marked Th2 cytokine responses are
markers of TB disease severity rather than of latent in-
fection [4, 31]. In addition, we found very low produc-
tion of the regulatory cytokine IL-10 and therefore a
remote possibility of on-going immune modulation by
M.tb in these contacts. In this study we used superna-
tants from the QFN assay to measure the different cy-
tokines. This assay is designed to measure IFNγ release
and may therefore not be optimal for measuring other
cytokines including IL-10.
Some studies have also demonstrated that healthy
contacts with stable latent tuberculosis infection
present with high Th1 and low Th2 cytokine profiles
caused by up-regulation of the IL-4 antagonist IL-4δ2
[2, 36]. Immune responses in people with latent tuber-
culosis vary with the different stages of infection [1, 37]
and may also be influenced by prior exposure to environ-
mental bacteria [30], the time since infection with M.tb
[38], the infective dose of M.tb [19], and the dynamic
status between controlling infection and progressing to
disease [39]. Prior exposure with BCG immunisation at
birth can also be an attributable factor to the sustained
high Th1 responses in this population [40]. Our baseline
findings are consistent with recent low-dose exposure to
Fig. 1 Flow diagram showing the recruitment and follow up process
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Table 1 Baseline characteristics of the household contacts with latent tuberculosis infection that were randomised to either the no
IPT or IPT arms
Variable Level No IPT (n = 23) n (%) IPT (n = 24) n (%)
Household contact relating factors
Sex Female 16 (70) 15 (63)
Male 7 (30) 9 (37)
Age (median) 25 24
Age group 6–12 3 (13) 4 (17)
13–18 3 (13) 3 (13)
>18 17 (74) 17 (70)
Socio-economic status Lower 11 (48) 10 (42)
higher 12 (52) 14 (58)
Relationship to index case First degree relative 18 (78) 20 (83)
Not first degree relative 5 (22) 4 (17)
Proximity to index case Shared meals with index case 0 2 (8)
Cared for index case 7 (30) 12 (50)
Shared room with index case 12 (52) 6 (25)
Shared bed with index case 4 (18) 4 (17)
Duration of contact with index case >6 h/day 22 (96) 20 (83)
<6 h/day 1 (4) 4 (17)
Smoking No 18 (78) 20 (83)
Yes 5 (22) 4 (17)
Alcohol No 15 (65) 17 (71)
Yes 8 (35) 7 (29)
BCG scar No 12 (52) 7 (29)
Yes 11 (48) 17 (71)
aBaseline cytokine responses (medians (IQR)) pg/ml IFNγ 1201.1 (336.8–2246.6) 648 (259.6–2605.4)
TNFα 1 (1–11.4) 6.8 (1–74.6)
IL-2 339.8 (138.4–415.2) 291.2 (80.6–444.4)
IL-5 2.1 (1–9.9) 1 (1–1)
IL-13 21.9 (2.3-35.3) 2.1 (1–10.6)
IL-10 1 (1–1) 1 (1–1)
IL-17a 1 (1–1) 1 (1–1.8)
IL-17f 3.8 (1–6.7) 1 (1–1.9)
IL-21 1 (1–1) 1 (1–1)
IL-22 1.1 (1–12.4) 1 (1–4.9)
M.tb specific antibody responses PPD 5200 (2950–8800) 5550 (3250–8200)
(medians (IQR)) ng/ml CFP-10 3100 (1500–4800) 2700 (2050–4900)
ESAT-6 5000 (2400–7900) 3700 (2550–5600)
Index case relating factors
HIV status of index case Negative 20 (87) 18 (82)
Positive 3 (13) 4 (18)
Sputum positivity 1+ 4 (17) 7 (29)
2+ 10 (43) 4 (17)
3+ 9 (40) 13 (54)
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M.tb infection among contacts with an effective, immune
controlling response to the M.tb infection [41]. This is
supported by the high rate of reversions of the TST even
in the no IPT arm, and lack of progression to active TB.
At the end of six months, we found that IPT led to a
decrease in the levels of Th1 cytokines and not of the
Th2 or regulatory cytokines as anticipated. Reduction
in IFNγ cytokine responses following IPT has been
demonstrated before [38, 42–45]. One possible explan-
ation is effective clearance of dormant M.tb by isonia-
zid, leading to a decline in circulating effector cells and
leaving only long-lived memory T cells which secrete
low Th1 cytokine concentrations on re-exposure to
M.tb antigens [46]. Added to this, it is possible that the
presence of BCG bacilli from previous immunisation at
birth sustains expression of CD4 effector memory cells,
and that clearance of BCG bacilli by isoniazid therapy
reduces the number of these cells [40]. A third possibil-
ity is a reduction in M.tb specific IFNγ and IL-2 produ-
cing T-cells [42, 47] due to isoniazid induced apoptosis
[48] however, this data has only been generated in one
animal study. There have been some concerns about
the reduction of M.tb related cytokine responses that
may be protective after treatment with isoniazid: this
Table 1 Baseline characteristics of the household contacts with latent tuberculosis infection that were randomised to either the no
IPT or IPT arms (Continued)
Duration of Index patient cough (weeks) 0–4 6 (26) 7 (29)
5–14 9 (39) 7 (29)
15–24 4 (17) 8 (33)
>25 4 (17) 2 (8)
aBaseline cytokine responses were obtained from QFN culture supernatants and are represented as net (antigen stimulated minus unstimulated) values
Fig. 2 Comparison of the change in M.tb-specific net IFNγ and IL-2 cytokine production between enrolment and after 6 months of follow up in
the no IPT or IPT treatment arms. Net cytokine production (after subtraction of spontaneous cytokine production) was determined in response to
TB antigens (ESAT-6, CFP-10 and TB7.7 (peptide 4)) in QFN supernatants tested for cytokine content using multiplex bead array between baseline
and end of six months among the household contacts with latent tuberculosis infection
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might increase the risk of M.tb re-infection or re-
activation, in settings with high exposure to M.tb [26, 27,
49]. Some studies have addressed this by prolonging the
duration of IPT [50, 51]. The incidence of acquiring active
TB following IPT or no IPT in these trials was similar in
the post IPT period, however these trials were in HIV
patients who are highly susceptible to acquiring active TB
disease. Effects might be different in HIV negative
individuals.
We found that IPT caused a relative decline in the
antibody concentration to CFP-10 between baseline and
follow up, which was similar with the anti-ESAT concen-
trations though the effect on the latter was statistically
weak. There was no effect of IPT on antibody concentra-
tions to PPD. The effect of treatment of active tubercu-
losis on M.tb-specific antibody responses is variable with
some studies showing a decrease [52, 53], while others a
sustained increase up to 2 years following chemotherapy
[54, 55]. In M.tb infection, CFP-10 and ESAT-6 secretory
antigens form a complex which is involved in mycobac-
terial virulence [56]. The fact that the decline in M.tb-
specific antibody responses was only seen with CFP-10
reflects an effect of IPT on M.tb specific responses. This
could be explained by antibody involvement in clearing
mycobacterial antigens by formation of antigen-antibody
complexes [57], though this may be more pronounced
for antigens such as LAM [58].
The PPD responses on the other hand may not only
be M.tb specific but could be due to exposure to envir-
onmental mycobacteria or non-tuberculosis mycobac-
teria (NTM). Also, even if the IPT led to a reduction in
PPD responses that are “M.tb specific”, this effect could
be “drowned” by the PPD responses induced as a result
of continuous exposure by NTM encountered in the
environment. We have previously shown high antibody
titres to PPD that were maintained for up to 40 years
after BCG immunisation [59]. The majority of our
household contacts were immunised with BCG and this
previous exposure (as well as prior exposure to environ-
mental mycobacteria) may have contributed to the sus-
tained antibody concentrations to PPD. It is also possible
that IPT led to mycobacterial killing and release of anti-
gens resulting in sustained antibody production to PPD
while, on the contrary, reducing exposure to the antigens
secreted by living organisms. Similar to T cell based
responses, antibody responses vary with the type of anti-
gen, stage and bacterial load of M.tb infection [60]. A
study with a longer follow up duration would be beneficial
to determine any later change in the PPD antibody
concentrations.
To assess the effect of IPT on reduction of tubercu-
losis infection, we analysed the change in QFN and
TST tests at the end of follow up. There was only one
QFN reversion, and this occurred in the IPT arm,
similar to another study conducted by Johnson, et al.,
in South Africa [43]. In our study, TST reversion was
more common in the IPT arm than in the no IPT arm,
but this was a weak difference. Johnson, et al., found
that it was common to obtain TST reversions follow-
ing IPT [41], and the average TST diameter for those
that reverted changed from 16.3 mm to 1.4 mm after
IPT, again similar to our study. There is still contra-
dictory evidence regarding the effect of IPT on TST
reactions. The earlier Public Health Service trials re-
ported in North America showed that reversions of
the TST reactions were as frequent in the placebo
groups as in the isoniazid groups, in keeping with our
results [25].
Table 2 The impact of isoniazid preventive therapy on the net cytokine responses at the end of six-months follow up among
household contacts with latent tuberculosis infection
Cytokine Mean at end of six months Mean at end of six months Adjusted mean difference at the end of six monthsa P-value
(pg/ml; 95 % CI) (pg/ml; 95 % CI) (pg/ml; 95 % CI)
No IPT (n = 17) IPT (n = 18)
IFN-γ 2003.6(372.7, 3634.4) 541.1 (290.8, 791.3) −1488.6(−2682.5, −294.8) 0.01
IL-2 337.0(167.3, 506.8) 193.9 108.5, 279.3) −213.1(−419.2, −7.0) 0.04
TNF-α 34.4(−10.6, 79.4) 55.6(−6.3, 117.6) 34.1(−40.0, 108.2) 0.36
IL-5 15.5(−3.8, 34.9) 1.1(0.8, 1.4) −21.2 (−53.9, 11.3) 0.20
IL-13 35.4(−3.2, 74.2) 5.1(0.9, 9.4) −45.4(−104.4, 13.4) 0.13
IL-10 1.0(0.9, 1.1) 3.3(−0.8, 7.6) 2.0 (−1.43, 5.4) 0.25
IL-17a 2.4(−0.4, 5.2) 1.5(0.7, 2.3) 0.4 (−0.4, 1.2) 0.33
IL-17f 12.3(3.3, 21.3) 10.2(−6.1, 26.6) −5.8(−17.5, 5.7) 0.32
IL-21 34.0(−22.7, 90.7) 123.8(−133.9, 381.6) −11.6(−40.9, 17.5) 0.43
IL-22 27.0(1.3, 52.7) 6.1(−0.2, 12.6) −6.8(−88.8, 75.0) 0.86
aThis is the expected value of the mean difference in cytokine level at six months, comparing participants who received IPT to those did not receive IPT, adjusting
for the baseline level of the cytokine and the BCG scar status. Each cytokine was analysed in a separate model, with bootstrapping to estimate the
confidence intervals
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This exploratory study included small numbers of
subjects in each IPT treatment arm giving us limited
power to draw solid conclusions. Apparent effects may
have occurred by chance, and real effects may have
been missed. For example, the TST reversion rate
appears to be higher in the IPT arm, but the p-valve
was not statistically significant. The small sample size
resulted mainly from our strict eligibility criteria which
required a household contact to be positive on both the
QFN and TST tests, yet there were a large number of
Fig. 3 Comparison of the change in M.tb-specific antibody production between enrolment and after 6 months of follow up in the no IPT or IPT
treatment arms. Antibody concentrations were determined in response to TB antigens (PPD, CFP-10 and ESAT-6) in QFN supernatants using an
IgG ELISA assay among the household contacts with latent tuberculosis infection
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household contacts that had discordant QFN and TST
test results. The impact of IPT in the subgroups posi-
tive only on QFN would be of interest. A larger study
would be warranted to investigate effects of IPT further.
Due to the nature of the study design, we were unable
to know the duration of latent tuberculosis infection
for each household contact. As discussed above, this is
important for the interpretation of our findings [1]. Pla-
cing a TST can influence subsequent immune responses
to mycobacterial antigen [61] but this is unlikely to
have biased our results since samples for QFN were
taken before the TST was placed at both time points,
and all participants had the same TST exposure. We
were unable to satisfactorily monitor for compliance to
the IPT. However, the observed differences between the
two arms are consistent with an effect of treatment
among the participants who were provided with the
drug.
Conclusions
These findings provide further evidence that there is
an effect of IPT on the Th1 cytokine responses to
M.tb-specific antigens, and the M.tb-specific antibody
concentration, particularly to CFP-10, but gives no
evidence of an effect on the Th2, regulatory and
Th17 cytokine profiles, or on M.tb-specific antibody
concentrations to PPD or ESAT-6. This could reflect
a reduction in the mycobacterial burden, and hence
be taken as a positive response to treatment, promot-
ing the desired outcome of disease prevention. Alter-
natively, these results might perhaps be a direct effect
of the drug. The implications of the decline in T cell
and antibody responses are not clear, given that cor-
relates of protection against tuberculosis are not well
defined [62, 63]. Longer follow up studies have been
carried out, mainly in the USA, which showed that
the risk of subsequent progress to active TB disease
reduced with IPT [24, 25]. We lack information from
similar studies carried out in highly TB-endemic set-
tings, where re-exposure is very common. Could a reduc-
tion in potentially protective immune responses increase
vulnerability upon re-exposure, possibly out-weighing the
benefit of preventing reactivation of latent infection? In
such settings, there might be value in a larger study inves-
tigating the risks and benefits of short term IPT for low
risk household contacts of patients with active TB.
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